alopecia

Posts

Alopecia Treatment Market 2019

Alopecia Treatment Market 2019

Alopecia Treatment Market 2019 – Teva Pharmaceutical Industries, Merck, Reddy’s Laboratories, Cipla, Cellmid, Himalaya Drug, Taisho Pharmaceutical Holdings

The new report on the global Alopecia Treatment market provides key insights into the Alopecia Treatment market.

The market report is ideal for customers looking to gain actionable insights into the market which can assist them in furthering their business.

The global report provides a detailed analysis of all the parameters within the Alopecia Treatment market. The market report pegs the global Alopecia Treatment market at US$ XX million at the end of 2018 and shall keep a good CAGR of XX% throughout the forecast period. The global report covers the forecast period from 2018 – 2025. At the end of the forecast period, the Alopecia Treatment market is projected to reach the value of US$ XX million.

Get Free PDF Sample Brochure @ decisionmarketreports.com/request-sample?productID=1011763

Various factors affecting the forecasted trend in the Alopecia Treatment market are discussed in detail with analysis of the same. The global market report covers all the drivers, trends, and challenges in the market within the analysis and for the elucidation of the forecast statistics. Furthermore, the global market report is dissected and analysed across its various segments such as by product type, by application, by end users, and by region.

In terms of product type, the global Alopecia Treatment market is segmented into the following:

• Topical Drugs
• Oral Drugs
• Injectable
• Hair Transplant Services
• Other

Product X is currently leading in terms of value and volume owing to high demand from across all regions. Product Y is expected to gain traction since new technology and changing customers trends is expected to push the demand for it. Product Y is hence is expected to record the highest growth rate for the forecast period.

In terms of application, the global Alopecia Treatment market is segmented as follows:

• Hospitals
• Dermatology And Trichology Clinics
• Home Care Settings
• Other

Application X holds the highest share in the global Alopecia Treatment market. Application Y is expected to record the highest growth rate and can even surpass the market share of Application X by the end of the forecast period.

By end users, the global Alopecia Treatment market is segmented into:

• Teva Pharmaceutical Industries
• Merck
• Johnson&Johnson
• Reddy’s Laboratories
• Cipla
• Cellmid
• Himalaya Drug
• Taisho Pharmaceutical Holdings

End-user X is the highest share holder in terms of value and volume and End-user Y is expected to record a high growth rate for the forecast period based on the data of the changing market trends.

The global Alopecia Treatment market report provides a detailed analysis of the regional segmentation. The Alopecia Treatment market is segmented into the following regions:

• United States
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

Region X is a more matured market and is the highest with US$ XX million in value at the end of 2018. Region Y is showcasing high growth rate as the overall income of the population is on the rise and people have a higher amount of disposable income available.

The global Alopecia Treatment market includes a detailed SWOT analysis and competitive landscape analysis as well that provides customers with key insights into what the top companies are working on. Every top player and their respective company profiles are covered in detail including the latest news and updates of acquisitions and mergers. For more details on the Alopecia Treatment market, visit our website here.

Table of Contents

Executive Summary

1 Alopecia Treatment Market Overview
2 Global Alopecia Treatment Market Competition by Manufacturers
3 Global Alopecia Treatment Production Market Share by Regions
4 Global Alopecia Treatment Consumption by Regions
5 Global Alopecia Treatment Production, Revenue, Price Trend by Type
6 Global Alopecia Treatment Market Analysis by Applications
7 Company Profiles and Key Figures in Alopecia Treatment Business
8 Alopecia Treatment Manufacturing Cost Analysis
9 Marketing Channel, Distributors and Customers
10 Market Dynamics
11 Global Alopecia Treatment Market Forecast
12 Research Findings and Conclusion
13 Methodology and Data Source

About Us

Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

 

Alopecia Treatment Market 2019

 

Source

 

Previous Posts

Alopecia Treatment Market 2019

Alopecia Treatment Market 2019

Alopecia Treatment Market 2019 – Teva Pharmaceutical Industries, Merck, Reddy’s Laboratories, Cipla, Cellmid, Himalaya Drug, Taisho Pharmaceutical Holdings

The new report on the global Alopecia Treatment market provides key insights into the Alopecia Treatment market.

The market report is ideal for customers looking to gain actionable insights into the market which can assist them in furthering their business.

The global report provides a detailed analysis of all the parameters within the Alopecia Treatment market. The market report pegs the global Alopecia Treatment market at US$ XX million at the end of 2018 and shall keep a good CAGR of XX% throughout the forecast period. The global report covers the forecast period from 2018 – 2025. At the end of the forecast period, the Alopecia Treatment market is projected to reach the value of US$ XX million.

Get Free PDF Sample Brochure @ decisionmarketreports.com/request-sample?productID=1011763

Various factors affecting the forecasted trend in the Alopecia Treatment market are discussed in detail with analysis of the same. The global market report covers all the drivers, trends, and challenges in the market within the analysis and for the elucidation of the forecast statistics. Furthermore, the global market report is dissected and analysed across its various segments such as by product type, by application, by end users, and by region.

In terms of product type, the global Alopecia Treatment market is segmented into the following:

• Topical Drugs
• Oral Drugs
• Injectable
• Hair Transplant Services
• Other

Product X is currently leading in terms of value and volume owing to high demand from across all regions. Product Y is expected to gain traction since new technology and changing customers trends is expected to push the demand for it. Product Y is hence is expected to record the highest growth rate for the forecast period.

In terms of application, the global Alopecia Treatment market is segmented as follows:

• Hospitals
• Dermatology And Trichology Clinics
• Home Care Settings
• Other

Application X holds the highest share in the global Alopecia Treatment market. Application Y is expected to record the highest growth rate and can even surpass the market share of Application X by the end of the forecast period.

By end users, the global Alopecia Treatment market is segmented into:

• Teva Pharmaceutical Industries
• Merck
• Johnson&Johnson
• Reddy’s Laboratories
• Cipla
• Cellmid
• Himalaya Drug
• Taisho Pharmaceutical Holdings

End-user X is the highest share holder in terms of value and volume and End-user Y is expected to record a high growth rate for the forecast period based on the data of the changing market trends.

The global Alopecia Treatment market report provides a detailed analysis of the regional segmentation. The Alopecia Treatment market is segmented into the following regions:

• United States
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

Region X is a more matured market and is the highest with US$ XX million in value at the end of 2018. Region Y is showcasing high growth rate as the overall income of the population is on the rise and people have a higher amount of disposable income available.

The global Alopecia Treatment market includes a detailed SWOT analysis and competitive landscape analysis as well that provides customers with key insights into what the top companies are working on. Every top player and their respective company profiles are covered in detail including the latest news and updates of acquisitions and mergers. For more details on the Alopecia Treatment market, visit our website here.

Table of Contents

Executive Summary

1 Alopecia Treatment Market Overview
2 Global Alopecia Treatment Market Competition by Manufacturers
3 Global Alopecia Treatment Production Market Share by Regions
4 Global Alopecia Treatment Consumption by Regions
5 Global Alopecia Treatment Production, Revenue, Price Trend by Type
6 Global Alopecia Treatment Market Analysis by Applications
7 Company Profiles and Key Figures in Alopecia Treatment Business
8 Alopecia Treatment Manufacturing Cost Analysis
9 Marketing Channel, Distributors and Customers
10 Market Dynamics
11 Global Alopecia Treatment Market Forecast
12 Research Findings and Conclusion
13 Methodology and Data Source

About Us

Decision Market Reports is a one-stop solution, covers market research studies of all the industries, companies and regions. DMR aims at providing quality research, and insights about every market to helps our clients in taking right decisions. Our repository consists of most trending industry reports, niche areas, and leading company profiles. A comprehensive collection of reports is updated daily to offer hassle-free access to our latest updated report databases.

 

Alopecia Treatment Market 2019

 

Source

 

Previous Posts

Hairmore Novel Treatment for Traction Alopecia

Hairmore Novel Treatment for Traction Alopecia

Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia

APPLIED BIOLOGY’S NOVEL TAAR RECEPTOR AGONIST TO HELP MILLIONS OF CHINESE WOMEN SUFFERING FROM PONYTAIL INDUCED ALOPECIA

Applied Biology, Inc. (“Applied Biology”) announced today it has entered into a license agreement for the Chinese market for its novel TAAR receptor agonist for the treatment of ponytail induced alopecia.

A recent study conduct by Dr. Goren et al. demonstrated, that approximately 79% of women wearing a ponytail hair style four or more times per week for a period of at least ten years are at high risk for developing ponytail induced alopecia (also known as traction alopecia). No treatment exists for this condition.

While cessation of styling the hair in a ponytail avoids the development of this condition, a large majority of Chinese women continue to wear a ponytail hair style; thus, a prophylactic treatment that prevents the development of ponytail induced alopecia is of great clinical importance. Recently, Applied Biology scientists discovered a novel TAAR receptor agonist that when applied to scalp reduces the force exerted by the ponytail on hair follicles; thus, reduces the likelihood of development of ponytail alopecia.

According to Dr. Goren, Chief Medical Officer of Applied Biology: “China is the world’s second largest hair market. We are excited to team with the Hairmore Group, China’s premier hair surgery and treatment centers, to provide this groundbreaking therapy to women.”

ABOUT APPLIED BIOLOGY

Founded in 2003, Applied Biology is a biotechnology company located in Irvine, CA focused on the development of novel innovations for the treatment of hair disorders. Our focused team of scientists and physicians, have made breakthroughs in genetics, molecular biology mechanisms and clinical dermatology that are poised to improve millions of patients’ lives.

ABOUT HAIRMORE

Hairmore Group operating 17 surgical centers and over 100 clinics is the leader in hair surgery and hair treatment in China. With focus on quality of care through innovation, Hairmore is expanding its clinical excellence center throughout China and the world.

Applied Biology to Enter into a License Agreement with Hairmore for its Novel Treatment for Traction Alopecia

 

Source

 

Previous Posts

Concert Pharmaceuticals Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

Concert Pharmaceuticals, Inc. today announced that interim clinical data from its CTP-543 Phase 2 trial in alopecia areata has been selected for an oral presentation at the Late-Breaking Research Program during the American Academy of Dermatology (AAD) Annual Meeting being held March 1 – 5, 2019 in Washington, D.C.

The details of the presentation are as follows:

  • Title: JAK Inhibitor CTP-543 Achieves Primary Endpoint in Phase 2 Trial in Alopecia Areata
  • Date and Time: Saturday, March 2, 2019, 1:00 – 4:00 p.m.
  • Session: S034: Late-Breaking Research: Clinical Trials
  • Room: Ballroom A
  • Abstract Number: 11291

About CTP-543

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jaka

fi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

About Alopecia Areata

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40.

It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders.

For more information please visit www.concertpharma.com

1 Fricke M. Epidemiology and Burden of alopecia areata: a systemic review. Clinical, Cosmetic and Investigational Dermatology. 2015; Vol 8. 397-403.

 

Concert Pharmaceuticals Selected for Late-Breaking Oral Presentation of CTP-543 Phase 2 Data in Alopecia Areata at 2019 AAD Annual Meeting

 

Source

 

Previous Posts

Phase 2a Trial of CTP-543 in Alopecia Areata

Phase 2a Trial of CTP-543 in Alopecia Areata

Concert Pharma (CNCE) Reports Complete Enrollment of 12mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that it has completed patient enrollment of the final cohort evaluating 12 mg twice daily of CTP-543 in its Phase 2a trial for the treatment of moderate-to-severe alopecia areata. The trial previously enrolled patients to receive 4 mg and 8 mg twice daily compared to placebo. Data from the Phase 2a trial including the 12 mg cohort is expected in the third quarter of 2019.

“It is important early on in our development program to identify the safest and most effective doses of CTP-543 for patients with a chronic autoimmune disease like alopecia areata. The evaluation of the twice daily 12 mg dose provides a comprehensive exploration of the relevant dose range for CTP-543 and positions us well for later stage development of the compound,” stated James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals.

The Phase 2a trial is a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. Patients were sequentially randomized to receive one of three doses of CTP-543 (4 mg, 8 mg, or 12 mg) or placebo twice daily. The primary outcome measure utilizes the severity of alopecia tool (SALT) after 24 weeks of dosing. Additional information about the trial is available on www.clinicaltrials.gov.

In November 2018, Concert reported positive interim topline results from the first two cohorts (4 mg and 8 mg twice daily) in its Phase 2a trial.

The 8 mg twice daily cohort achieved the primary endpoint of ≥ 50% relative reduction in overall severity of alopecia tool (SALT) score from baseline at 24 weeks in 47% of patients compared to 8.6% of placebo patients (p <0.001).

The 4 mg twice daily CTP-543 cohort had numerically higher responses than placebo but was not statistically better than placebo. Regrowth of hair did not appear to plateau at Week 24. Treatment with CTP-543 was generally well tolerated. No serious adverse events were reported. Additional information about the CTP-543 Phase 2a results is available in the Scientific Presentations section of the Company’s website.

About CTP-543 and Alopecia Areata

CTP-543 was discovered by applying Concert’s deuterium chemistry technology to modify ruxolitinib, a drug which selectively inhibits Janus kinases 1 and 2 (JAK1 and JAK2) and is commercially available under the name Jakafi® in the United States for the treatment of certain blood disorders. Deuterium modification of ruxolitinib was found to alter its human pharmacokinetics in ways which may enhance its use as a treatment for alopecia areata. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543.

Alopecia areata is an autoimmune disease that results in partial or complete loss of hair on the scalp and body that may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life with the majority of patients initially having symptoms by age 40. It is believed to equally affect both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the U.S. Food and Drug Administration’s (FDA) Patient-Focused Drug Development Meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Enrollment of 12mg Cohort in Phase 2a Trial of CTP-543 in Alopecia Areata

Source

Previous Posts

Treatment of alopecia universalis

Treatment of alopecia universalis

Treatment of alopecia universalis with topical Janus kinase inhibitors – a double-blind, placebo, and active-controlled pilot study

Background

Oral Janus kinase (JAK) inhibitors are currently being investigated in phase II and phase III clinical trials for several inflammatory skin diseases including alopecia areata (AA). Topical JAK inhibitors have been investigated in atopic dermatitis, psoriasis, and AA. While a number of case series using topical JAK inhibitors in AA have been published, to date there have been no randomized controlled clinical trials.

Methods

We conducted a phase I, 28-week prospective, placebo‐controlled, double‐blind study in patients with alopecia universalis investigating hair regrowth with two topical JAK inhibitors, 2% tofacitinib and 1% ruxolitinib. Topical clobetasol dipropionate 0.005% was the active comparator while vehicle was used as the placebo control. Sixteen patients were recruited for the study.

Results

Six patients demonstrated partial hair regrowth in areas treated with 2% tofacitinib ointment applied twice daily.

Five patients demonstrated partial hair regrowth in the areas treated with 1% ruxolitinib ointment.

Ten patients demonstrated partial hair regrowth in the areas treated with clobetasol dipropionate 0.05% ointment.

No regrowth was observed in the placebo-treated area. Interestingly, generalized hair regrowth was observed in two patients.

One patient had 100% regrowth over his entire scalp and eyebrows by week 24 but relapsed after 12 weeks.

A second patient also experienced generalized scalp regrowth and significant eyebrow growth and continued to maintain growth 14 weeks later.

Conclusion

Our findings suggest that topical JAK inhibitors could be developed as a potential new treatment for AA and alternative to clobetasol dipropionate 0.05% ointment.

Treatment of alopecia universalis with topical Janus kinase inhibitors – a double-blind, placebo, and active-controlled pilot study

Source

Previous Posts

Aclaris Therapeutics Provides Update on Clinical Trials

Aclaris Therapeutics Provides Update on Clinical Trials

Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials

Aclaris Therapeutics a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology, today provided updated data from three clinical trials for ATI-502, an investigational topical Janus kinase (JAK) 1/3 inhibitor, an update on the expected release of topline data for one clinical trial for ATI-502, and an enrollment update for a clinical trial for ATI-501, an investigational oral JAK 1/3 inhibitor.

AA-202 Topical and AUATB-201 Topical are ongoing Phase 2 clinical trials of ATI-502 for the treatment of alopecia areata (AA) in the United States and Australia, respectively.

In AA-202 Topical, 11 patients with the more severe forms of AA, alopecia universalis (AU) and alopecia totalis (AT), were treated with ATI-502 in an initial double-blind pharmacokinetic and pharmacodynamic study for 28 days before entering a 12-month open-label extension.

In AUATB-201 Topical, an open-label clinical trial, 12 patients with eyebrow loss due to AA, including patients with AU or AT, had their eyebrows treated with ATI-502 for 6 months. VITI-201 Topical is an open-label pilot clinical trial of ATI-502 administered twice daily in 34 patients with non-segmental facial vitiligo.

As announced in November, Aclaris completed enrollment of AA-201 Topical, a randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and dose response of two concentrations of ATI-502 for the treatment of AA. This trial enrolled 129 patients with patchy AA, who were randomized to receive either ATI-502 or placebo.

The primary efficacy endpoint is the mean change from baseline in the Severity of Alopecia Tool (SALT) score at Week 24. Topline data from the AA-201 Topical trial are now expected in the second quarter of 2019.

In addition, Aclaris announced today that it has completed enrollment of AUAT-201 Oral, a randomized, double-blinded, parallel-group, placebo-controlled trial to evaluate the safety, efficacy and dose response of three concentrations of ATI-501 oral suspension for the treatment of AA. This trial enrolled 87 patients with AA, including AT and AU, who were randomized to receive either ATI-501 or placebo. The primary efficacy endpoint is the mean change from baseline in the SALT score at Week 24. Topline data from the AUAT-201 Oral trial are now expected in the third quarter of 2019.

“AA can be a psychologically devastating disease for which many patients do not have adequate options for treatment. Inhibition of the JAK1 and JAK3 pathways is an emerging therapeutic approach. We continue to advance our development programs for oral and topical formulations of JAK inhibitors with the goal of addressing the full spectrum of disease severity for patients living with AA,” said Dr. David Gordon, Chief Medical Officer of Aclaris.

Aclaris to Host Conference Call

Management will conduct a conference call at 5:00 PM ET today to discuss these updates.  The conference call will be webcast live over the Internet and can be accessed on the Events section of the Investors page of the Aclaris website at https://investor.aclaristx.com/events. A replay of the webcast will be archived on the Aclaris website for 30 days following the call. An accompanying slide deck with photos will be included as an exhibit to a Current Report on Form 8-K that Aclaris will furnish to the SEC today.

About Alopecia Areata

Alopecia areata (AA) is an autoimmune disease characterized by partial or complete loss of hair on the scalp, face or body. The scalp is the most commonly affected area. Onset of AA may occur in childhood and most patients experience onset by age 40. The course of disease is unpredictable and may involve spontaneous hair regrowth and sudden hair loss. Over half of patients with AA experience poor health-related quality of life. The disease can be associated with serious psychological consequences, including anxiety and depression. AA affects up to 1.8% of people in the United States and 2.0% of people globally at some point during their lives.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company focused on identifying, developing, and commercializing innovative therapies to address significant unmet needs in dermatology, both aesthetic and medical, and immunology. Aclaris’ focus on market segments with no FDA-approved medications or where treatment gaps exist has resulted in the first FDA-approved treatment for raised seborrheic keratoses and several clinical programs to develop medications for the potential treatment of common warts, alopecia areata, and vitiligo. For additional information, please visit www.aclaristx.com and follow Aclaris on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements

Aclaris Therapeutics Provides Update on Oral and Topical JAK 1/3 Inhibitor Clinical Trials

Source

 

Previous Posts

[print-me target=”body”]

Alopecia Market Research 2018

Alopecia Market Research 2018

Alopecia Market Research 2018 with top Countries data: Region Wise Analysis of Top Players in Market by its Types and Application and Forecast to 2023

Alopecia Market provides deep understanding, clarifies varieties of the market to help you decide not only the succeeding strategy but also to achieve the desired market position. This market research is a combined result of inputs from industry experts with awareness, the experience of Alopecia market and qualitative and quantitative synthesis of the market.

Description: Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues.

Top key players of the industry are covered in Alopecia Market Research Report:

  • Lifes2good, Kirkland Signature, Johnson & Johnson, Dr. Reddy’s Laboratories., Cipla., Alpecin., Vitabiotics., Sun Pharma., Phyto Ales Group…

The worldwide market for Alopecia Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2018.

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into:

  • Oral treatment, Topical treatment, Other treatment…

Split by application, this report focuses on consumption, market share and growth rate of Alopecia market in each application and can be divided into:

  • Male, Female

Global Alopecia Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

  • North America (the USA, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America (Brazil, Argentina, Columbia, etc.)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Target Audience of Alopecia Market:

  • Manufacturer / Potential Investors
  • Traders, Distributors, Wholesalers, Retailers, Importers, and Exporters.
  • Association and government bodies.

Alopecia Market Influencing Factors:

  • Market Environment: Government Policies, Technological Changes, Market Risks.
  • Market Drivers: Growing Demand, Reduction in Cost, Market Opportunities and Challenges.

Key questions answered in the Alopecia Market report:

  • What will the Alopecia market size and the growth rate be in 2023?
  • What are the key market trends impacting the growth of the Alopecia market?
  • Who are the global key manufacturers of Alopecia industry: Company Introduction, Product Specification, and Major Types Analysis, Production Market Performance, Sales Market Performance, Contact Information.
  • What are the types and applications of Alopecia? What is the market share of each type and application: production, revenue, price, Market Size (Sales) Market Share by Type.
  • What are the upstream raw materials and manufacturing equipment of Alopecia? Up Stream Industries Analysis, Raw Material and Suppliers, Equipment and Suppliers, Manufacturing Analysis, Manufacturing Process, Manufacturing Cost Structure, Manufacturing Plants Distribution Analysis, Industry Chain Structure Analysis
  • What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Alopecia?
  • What are the Alopecia market opportunities and threats faced by the vendors in the global Alopecia Industry?

Alopecia Market Research 2018 with top Countries data

Source

Global Alopecia Market Professional Survey

Global Alopecia Market Professional Survey

Global Alopecia Market Professional Survey Report 2018

Research Methodology

Global Alopecia market is anticipated to grow at a CAGR of XX% by 2023, according to a new report published by Marketintelligencedata Inc. The report segments the market and forecasts its size, by volume and value, on the basis of application, by-products, and by geography (North America, Europe, Asia-Pacific, MEA and South America).

The Global Market for Alopecia to 2023 offers detailed coverage of guanidine Alopecia industry and presents main market trends. The market research gives historical and forecast market size, demand and production forecasts, end use demand details, price trends, and company shares of the leading Alopecia producers to provide exhaustive coverage of the guanidine carbonate.

This research report includes the following contents:

  • Alopecia Product details, including pictures and technical specifications
  • Alopecia manufacturers, distributors, and channels
  • Major players present in the Alopecia
  • Information on competitor market shares, revenue, unit sales, etc
  • Breakdown by applications for the Market
  • Value chain and distributor details in the market

Key vendors:

  • Lifes2good
  • Kirkland Signature
  • Johnson & Johnson
  • Dr. Reddy’s Laboratories.
  • Cipla.
  • Alpecin.
  • Vitabiotics.
  • Sun Pharma.
  • Phyto Ales Group

Key regions:

North America, Europe, China, Japan, India, Southeast Asia, Other regions (Central & South America, Middle East & Africa)

Additionally, the market is segmented by the following sectors

  • Oral treatment
  • Topical treatment
  • Other treatment

Not only this, figures covering the end-user applications are also provided according to the following classification

  • Male
  • Female

In summary, the report serves to study and analyze the Alopecia size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

Overall the report is an excellent source for managers, researches and top executives alike to analyze and get clarity on the market standings and business forecast. We provide the information after thorough research and analysis saving precious hours and budget for the companies. We have been serving major clients like Sony, BCG, PWC, Mck, Hewlett Packard, Technicolor Etc.

Global Alopecia Market Professional Survey Report 2018

Source

Alopecia Treatment Market Outlook

Alopecia Treatment Market Outlook

Alopecia Treatment Market Outlook; Development Trends, Market Demands & Forecast by 2023 Industry Key players

Alopecia Treatment Market By Disease Type (Androgenic Alopecia, Cicatricial Alopecia, Alopecia Areata, Traction Alopecia and Alopecia Totalis) By Treatment Type (Topical Drugs, Injectable, Low Level Laser Therapy, Oral Drugs and Hair Transplant Services) By End-User (Homecare Settings, Dermatology Clinics and Others)- Global Industry Analysis & Forecast to 2023

Alopecia Treatment Market: Industry Outlook and Trend Analysis

The Alopecia Treatment Market has encountered significant development in recent years and is anticipated to grow tremendously over the forecast period. Alopecia also recognized as hair-loss or baldness is a medicinal condition that alludes to the loss of hairs from the head or any part of the body. The condition can happen in both male and female and at any age.

There are five main kinds of alopecia to be specific; androgenic alopecia, cicatricial alopecia, androgenic alopecia, alopecia totalis, and traction alopecia. Development of the alopecia treatment market is fundamentally determined by expanding interest in hair loss treatment drugs with improved viability and insignificant reactions. For instance, as of late cytokine therapy too regenerative cell treatment is picking up demand for treatment of different sorts of alopecia.

Alopecia Treatment Market Competitive Insights:

The leading players in the market are Ranbaxy Laboratories, Dr. Reddy’s Laboratories, Nanogen, Merck & Co, Vitabiotics, Viviscal, Kirkland Signature, Cipla, Phyto – Alès Groupe and Johnson and Johnson. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

Alopecia Treatment Market: Treatment Type Outlook

Topical medications incorporate lotions, gels, creams, foam, and shampoos, while the injectable treatment composes section incorporates steroids, platelet-rich plasma therapy, and injectable fillers. Propecia, an oral drug is at present the main FDA affirmed medication in the treatment of alopecia. Restricted clinical efficacy exhibited by such medicines would hamper market and income development of established products over the figure time frame.

Alopecia Treatment Market: End User Outlook

Dermatology and trichology clinics section is the most elevated income supporter of the alopecia treatment market trailed by home care settings and end-user portions. Over the counter distribution and rising level of e-Commerce, implementation is anticipated to prompt an expanded selection of topical hair loss treatments in home care settings.

Alopecia Treatment Market: Regional Outlook and Trend Analysis

North America, trailed by Europe, is foreseen to overwhelm the alopecia treatment market all through the conjecture time frame. The Asia Pacific is anticipated to witness the speediest development attributable to the upheaval of a middle-aged populace in the area. Likewise, the district is observing sound development as far as GDP, which is anticipated to move development at solid digits. The Middle East and Africa and Latin America are foreseen to encounter sluggish development amid the conjecture time frame.

Major Table of Contents:

Chapter1. Introduction

Chapter2. Executive Summary

Chapter3. Market Overview

Chapter4.Market Analysis by Regions

Chapter5. Alopecia Treatment Market, By Disease Type

Chapter6. Alopecia Treatment Market, By Treatment Type

Chapter7. Alopecia Treatment Market, By End User

Chapter8. Alopecia Treatment Market, By Region

Alopecia Treatment Market Research Methodology:

We use both primary as well as secondary research for our market surveys, estimates and for developing the forecast. Our research process commences by analyzing the problem which enables us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to the changing nature of products and markets while retaining the core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers a one-stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Alopecia Treatment Market Outlook

Source

Samumed Doses First Subject in Phase 2/3 Trial of SM04554

Samumed Doses First Subject in Phase 2/3 Trial of SM04554

Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia

Samumed, LLC, announced today that it has dosed the first subject in its phase 2/3 trial of SM04554, a topical small molecule Wnt pathway activator, for the treatment of androgenetic alopecia (AGA), the most common type of hair loss in men and women. This trial is being conducted as a pivotal study in Turkey and is expected to enroll approximately 625 patients across 11 study sites.

This study is conducted under an IND with the FDA. In addition, the Ministry of Health of Turkey has confirmed that the study, if successful, would support submission of a marketing application for SM04554 in Turkey.

“We have shown in phase 2 trials that daily treatment with SM04554 appeared safe and increased follicle counts and non-vellus hair counts compared to vehicle in males with AGA after 90 days of exposure,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “In order to build upon these results, this study will evaluate the effect of treatment with topical SM04554 applied daily for 48 weeks on males with AGA. We anticipate top-line results in the second half of 2020.”

This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of topical SM04554 solution (0.15% & 0.25%) applied daily to the scalp of male AGA subjects. The trial is a 54-week study, with 48 weeks of treatment followed by 6 weeks of follow-up. The primary endpoint of the study is the baseline-adjusted absolute non-vellus hair count in the target area by phototrichogram analysis at Week 48 compared to vehicle.

Prof. Server Serdaroglu, M.D., principal investigator in this study, said, “The negative psychological effects of androgenetic alopecia are well documented. Currently available treatments have limited efficacy and patients need access to better options. We look forward to contributing to this important clinical study which will examine the effects of SM04554 over the course of one year.”

Samumed has completed two phase 2 studies examining the safety, tolerability, and efficacy of SM04554 for the treatment of AGA. These studies demonstrated that treatment with SM04554 appeared to be well-tolerated and safe. Key clinical results have shown that treatment with SM04554 applied daily (90 days) to the scalp resulted in:

About Androgenetic Alopecia

Androgenetic alopecia (AGA) is the most common type of hair loss in men and women, affecting an estimated 50 million men and 30 million women in the US. It is characterized by varying degrees of hair thinning that occurs as terminal (mature) hairs are gradually “miniaturized” to vellus (fine/wispy) and dormant hairs. AGA generally presents in a characteristic pattern and varies by age and race. It is most prevalent among Caucasians, with approximately half of men developing hair loss by age 50 and one-third of women developing some form of loss as age increases.

About SM04554

SM04554 is a topical small molecule Wnt pathway activator being developed for the treatment of androgenetic alopecia (AGA). Additional information on Samumed’s SM04554 AGA program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=16

About Samumed

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.

Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at: https://www.samumed.com/pipeline/default.aspx

Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia

Source